Cocrystal Pharma (COCP) Amortization of Deferred Charges (2011 - 2026)

Cocrystal Pharma has reported Amortization of Deferred Charges for 8 years, with the latest figure at $79000.0 in Q1 2026.

• Quarterly Amortization of Deferred Charges rose 6.76% year-over-year to $79000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $262000.0 (up 10.55% YoY) and the FY2012 annual result came in at $36304.0, down 77.37% from the prior year.
• Amortization of Deferred Charges rose to $79000.0 in Q1 2026 per COCP's latest filing, from $74000.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $79000.0 in Q1 2026 and troughed at $49000.0 in Q1 2022.
• A 4-year average of $58375.0 and a median of $54000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
• The sharpest annual moves came in 2022 and 2023: Amortization of Deferred Charges gained 4.26% in 2022, then climbed 10.2% in 2023.
• Over 4 years, Amortization of Deferred Charges stood at $51000.0 in 2022, then increased by 7.84% to $55000.0 in 2023, then soared by 34.55% to $74000.0 in 2025, then advanced by 6.76% to $79000.0 in 2026.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $79000.0, $74000.0, and $55000.0 for Q1 2026, Q1 2025, and Q3 2023 respectively.